MOLOGEN AG (ISIN DE0006637200) has succeeded in considerably improving the transport and storage suitability of their therapeutics for cell-based gene therapy. The improvements were made possible by technological advancements. Due to this breakthrough, the products can now be manufactured at locations remote from the sites of their employment in therapy. This considerably increases the circle of potential licensees and thus, the scope of the rewards model. Based on these developments, MOLOGEN has decided to focus exclusively on a location-independent license model for their cell-based gene therapy. MOLOGEN expects to tap considerable potential with this approach, especially in regions with strong economic growth.
